-
Expert Opin Investig Drugs · Mar 2011
Comment Multicenter Study Controlled Clinical TrialCystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
- Sabina Antonela Antoniu.
- University of Medicine and Pharmacy Gr. T. Popa Iasi, Pulmonary Disease University Hospital, Department of Internal Medicine II-Pulmonary Disease, 30 Dr I Cihac Str., Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
- Expert Opin Investig Drugs. 2011 Mar 1;20(3):423-5.
IntroductionSeveral types of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene lead to abnormal CFTR protein and alterations of chloride and sodium transmembrane transportation in cystic fibrosis (CF). Some investigational compounds such as VX-770 can improve CFTR protein function.Areas CoveredThis paper discusses the results of a Phase II study investigating the safety and efficacy of VX-770 in patients with CF.Expert OpinionVX-770 is able to improve chloride and sodium transportation and has a good safety profile. Although such compounds have limited therapeutic targeting potential, preliminary results show great promise in the context of CF therapy.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.